

# BMJ Open Prevalence of atypical pathogens in patients with severe pneumonia: a systematic review and meta-analysis

Sidan Wang <sup>1</sup>, Jiaoqi Tang,<sup>2</sup> Yurong Tan,<sup>3</sup> Zhi Song,<sup>1</sup> Ling Qin<sup>4</sup>

**To cite:** Wang S, Tang J, Tan Y, *et al.* Prevalence of atypical pathogens in patients with severe pneumonia: a systematic review and meta-analysis. *BMJ Open* 2023;**13**:e066721. doi:10.1136/bmjopen-2022-066721

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-066721>).

SW and JT contributed equally.

Received 20 July 2022

Accepted 28 March 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>The Second Department of Gastrointestinal Surgery, Third Xiangya Hospital, Central South University, Changsha, Hunan, China

<sup>2</sup>Emergency Department, Zhuzhou Central Hospital, Zhuzhou, Hunan, China

<sup>3</sup>Department of Medical Microbiology, School of Basic Medical Sciences, Central South University, Changsha, Hunan, China

<sup>4</sup>Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China

## Correspondence to

Dr Zhi Song;  
13069778@qq.com

## ABSTRACT

**Objectives** We aimed to summarise the prevalence of atypical pathogens in patients with severe pneumonia to understand the prevalence of severe pneumonia caused by atypical pathogens, improve clinical decision-making and guide antibiotic use.

**Design** Systematic review and meta-analysis.

**Data sources** PubMed, Embase, Web of Science and Cochrane Library were searched through November 2022.

**Eligibility criteria** English language studies enrolled consecutive cases of patients diagnosed with severe pneumonia, with complete aetiological analysis.

**Data extraction and synthesis** We conducted literature retrieval on PubMed, Embase, Web of Science and The Cochrane Library to estimate the prevalence of *Chlamydia*, *Mycoplasma* and *Legionella* in patients with severe pneumonia. After double arcsine transformation of the data, a random-effects model was used for meta-analyses to calculate the pooled prevalence of each pathogen. Meta-regression analysis was also used to explore whether the region, different diagnostic method, study population, pneumonia categories or sample size were potential sources of heterogeneity.

**Results** We included 75 eligible studies with 18 379 cases of severe pneumonia. The overall prevalence of atypical pneumonia is 8.1% (95% CI 6.3% to 10.1%). In patients with severe pneumonia, the pooled estimated prevalence of *Chlamydia*, *Mycoplasma* and *Legionella* was 1.8% (95% CI 1.0% to 2.9%), 2.8% (95% CI 1.7% to 4.3%) and 4.0% (95% CI 2.8% to 5.3%), respectively. We noted significant heterogeneity in all pooled assessments. Meta-regression showed that the pneumonia category potentially influenced the prevalence rate of *Chlamydia*. The mean age and the diagnostic method of pathogens were likely moderators for the prevalence of *Mycoplasma* and *Legionella*, and contribute to the heterogeneity of their prevalence.

**Conclusions** In severe pneumonia, atypical pathogens are notable causes, especially *Legionella*. The diagnostic method, regional difference, sample size and other factors contribute to the heterogeneity of prevalence. The estimated prevalence and relative heterogeneity factors can help with microbiological screening, clinical treatment and future research planning.

**PROSPERO registration number** CRD42022373950.

## INTRODUCTION

Severe pneumonia is associated with high mortality, as well as pulmonary and

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This is the first systematic review and meta-analysis to provide a comprehensive estimate of the prevalence of atypical pathogens in patients with severe pneumonia.
- ⇒ Unlike previous global reports, included data in this study is not limited to studies conducted in developed countries and the data from developing countries are also included.
- ⇒ We used subgroup analysis and meta-regression analysis to assess the potential cause of heterogeneity.
- ⇒ The lack of a widely and internationally adopted criteria for the diagnosis of severe pneumonia is likely to affect the inclusion and exclusion of eligible studies.
- ⇒ The substantial heterogeneity was not fully explained by the variables examined.

extrapulmonary complications.<sup>1</sup> Despite the rapid development of critical care medicine, severe pneumonia continues to pose a serious threat to human health. According to a US report, more than 1.5 million patients have been hospitalised annually due to community-acquired pneumonia (CAP); 17.1% of these are admitted to the intensive care unit (ICU), 60.4% are scored as Pneumonia Severity Index risk class IV or V and CAP is thought to be the primary cause of one out of every three in-hospital deaths.<sup>2</sup> The incidence of atypical pathogens in CAP patients worldwide (including inpatients and outpatients) is about 22%.<sup>3</sup> Population-based surveillance for CAP requiring hospitalisation from 2010 to 2012 in the USA revealed that approximately 21% of adults<sup>4</sup> and children<sup>5</sup> required intensive care. The most common pathogens in hospitalised adults with CAP are viruses (15%) and *Streptococcus pneumoniae* (5%), but atypical pathogens (*Mycoplasma pneumoniae*, *Legionella pneumophila* and *Chlamydia pneumoniae*) also account for 4%.<sup>4</sup> Among children aged 5 or older, *M. pneumoniae* is the most commonly detected (19%).<sup>5</sup> Although

the infection of atypical pathogens in severe pneumonia is not the most common, it can nonetheless cause serious complications, not only in the elderly but also in healthy adults.<sup>6 7</sup>

*Chlamydia pneumoniae*, *Chlamydia psittaci* and *Chlamydia trachomatis* are the most common species in the *Chlamydiaceae* family that are pathogenic to humans; these species can infect the respiratory tract and reproductive tract, cause trachoma, pneumonia and digestive disorders.<sup>8</sup> Children may have a higher frequency of infection with *C. pneumoniae*.<sup>9 10</sup> However, recent studies suggest that the prevalence of *Chlamydia* infection is probably underestimated due to a lack of awareness<sup>11–13</sup> or testing limitations.<sup>14</sup> In addition, some studies suggest that *Chlamydia* infection is a risk factor for asthma,<sup>15</sup> Alzheimer's disease<sup>16</sup> and cardiovascular disease.<sup>17</sup> *M. pneumoniae* infections are relatively more common than *Chlamydia* infections, with seasonal epidemic characteristics, and they exhibit a higher proportion of infections in young people (5–20 years of age).<sup>3 5</sup> However, in some countries, patients over the age of 25 also show a high prevalence.<sup>18</sup>

Legionnaires' disease, caused by *Legionella* bacteria, always manifests as severe atypical pneumonia and systemic infections, with a high percentage of patients requiring ICU admission.<sup>19</sup> The mortality rate of *Legionella* pneumonia is about 10%,<sup>20</sup> and higher in patients admitted to ICU at 20%.<sup>21</sup> The prevalence of Legionnaires' disease is seasonal, mostly occurring in the summer and early autumn.<sup>22</sup> Data from the US indicates that the incidence of Legionnaires' disease increased by 192% between 2000 and 2009.<sup>23</sup> Compared with 0.48 cases/100 000 population during 1992–2002, its average incidence soared to 2.71 cases/100 000 in 2018.<sup>24</sup>

Previous studies indicated variations in the prevalence of atypical pathogens in severe pneumonia in different groups, but mostly restricted to certain regions or only focused on a single pathogen, like *Legionella*. Prior reviews or meta-analysis about the prevalence of atypical pathogens in severe pneumonia is lacking. Understanding of the prevalence of infected pathogen is necessary when applying empirical antibiotic treatment in severe pneumonia.

Recommendations about the antibiotic treatment in severe pneumonia should be based on the best available evidence. To improve clinical decision-making and guide empirical antibiotic use, we systematically reviewed the prevalence of atypical pathogens, mainly *Chlamydia*, *Mycoplasma* and *Legionella*, in patients with severe pneumonia. We also explored the potential causes for differences between the original studies through meta-regression analysis, and investigated whether the prevalence was associated with the year of publication, study regions, mean age, study population, sample size, pneumonia categories and diagnostic methods.

## METHODS

### Search strategies and screening criteria

We searched PubMed, Embase, Web of Science and The Cochrane Library for publications to identify studies that contain information on the prevalence of the atypical pathogen in severe pneumonia. All the studies were published before 13 November 2022. The search strategy is described in online supplemental material 1. We also manually screened the reference lists of review articles identified through previous searches. Our analysis process complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.<sup>25</sup>

Two reviewers (SW and JT) independently screened the titles and abstracts of all potentially eligible studies with support from a third reviewer (LQ). After the exclusion of studies according to the eligibility criteria, full-text articles were assessed by the same reviewers. The inclusion criteria are as follows: studies enrolled consecutive cases of patients diagnosed with severe pneumonia, conducted a complete aetiological analysis and provided information on the prevalence of *Chlamydia*, *Mycoplasma* or *Legionella*. We also confirmed that the studies definitively tested for at least one atypical pathogen. The pathogen detection methods in all the literature are all recognised as meeting the testing guidelines. We excluded studies if they targeted specific populations, such as elderly individuals, post-transplant populations and patients requiring mechanical ventilation, or if atypical pathogenic infections were grouped and prevalence was not available separately for *Chlamydia*, *Mycoplasma* and *Legionella*. We also excluded non-English reports when reviewing the full texts. The protocol of this meta-analysis was published in PROSPERO (International Prospective Register for Systematic Reviews).

### Data extraction and quality assessment

Data extraction was a multistep process based on the eligibility criteria. Two investigators (SW and JT) were responsible for the main research, and they independently extracted data onto a standardised form that included data related to study characteristics, including published year, mean age, geographical region, study population, diagnostic criteria, classification of severe pneumonia and diagnostic methods of *Chlamydia*, *Mycoplasma* and *Legionella* spp. Extracted data were compared, whereas disagreements between the two investigators were resolved through consensus discussion.

A modified version of an 11-item checklist recommended by the Agency for Healthcare Research and Quality (AHRQ) was used to evaluate the risk of bias in non-randomised studies.<sup>26–28</sup> All studies that met the inclusion criteria for analyses were assessed for risk of bias by the AHRQ checklist. An item would be scored '1' if it was answered 'Yes'; if it was answered 'No' or 'Unclear', then the item scored '0'. Article quality was assessed as follows: low quality=0–3; moderate quality=4–7; high quality=8–11 (online supplemental material 2 and table 1). All studies were independently rated by SW and JT, and checked

**Table 1** Univariate meta-regression for prevalence of *Chlamydia*, *Mycoplasma* and *Legionella* in patients with severe pneumonia

Covariate	Estimate (%)	Lower 95% CI	Upper 95% CI	P value	R <sup>2</sup> (%)
<i>Chlamydia</i> (n=49)					
Year of publication	-0.12	-0.43	0.18	0.42	4.55
Sample size (continuous)	-0.01	-0.02	0.00	0.03	2.35
Sample size (≥100 vs <100)	-6.02	-12.71	0.67	0.08	3.19
Mean age	-0.06	-0.26	0.14	0.58	0.43
Population (adults vs children)	-3.05	-10.29	4.19	0.41	24.03
Region (Asia vs others)	12.08	0.15	24.02	0.05	42.22
Category (others vs CAP)	-9.85	-17.06	2.64	0.01	13.14
Diagnostic method (others vs culture)	3.09	-3.39	9.57	0.35	0.00
Diagnostic method (PCR vs others)	-11.30	-17.59	-5.01	0.004	9.66
<i>Mycoplasma</i> (n=62)					
Year of publication	0.21	-0.14	0.55	0.24	1.35
Sample size (continuous)	-0.00	-0.01	0.01	0.79	0.00
Sample size (≥100 vs <100)	-0.88	-8.38	6.62	0.82	0.00
Mean age	-0.18	-0.34	-0.03	0.01	26.91
Population (adults vs children)	6.50	-1.73	14.90	0.12	8.95
Region (Asia vs others)	0.15	-0.47	30.98	0.06	39.58
Category (others vs CAP)	-5.43	-14.27	3.41	0.23	4.08
Diagnostic method (others vs culture)	2.84	-4.62	10.31	0.46	0.00
Diagnostic method (PCR vs others)	0.96	-6.60	8.51	0.80	0.00
<i>Legionella</i> (n=57)					
Year of publication	-0.49	-0.76	-0.21	0.0001	6.01
Sample size (continuous)	-0.01	-0.02	0.00	0.04	0.46
Sample size (≥100 vs <100)	-7.58	-13.58	-1.59	0.01	8.89
Mean age	-0.42	-0.70	0.13	0.004	7.73
Population (adults vs children)	-9.10	-19.11	0.92	0.08	9.51
Region (Asia vs others)	5.66	-14.39	25.71	0.58	13.09
Category (others vs CAP)	-1.09	-8.35	6.17	0.77	0.00
Diagnostic method (others vs culture)	1.24	-4.88	7.36	0.69	4.50
Diagnostic method (PCR vs others)	-10.53	-16.66	-4.40	0.008	21.22

CAP, community-acquired pneumonia; PCR, polymerase chain reaction.

by LQ to resolve any disagreements. We extracted the prevalence of each pathogen or the pool prevalence of atypical pathogens in the category of severe pneumonia, and calculated the rate by the number of cases and total participants in those without exact prevalence.

### Statistical analysis

The pooled and separate prevalence of atypical pathogens (*Chlamydia*, *Mycoplasma* and *Legionella*) in severe pneumonia were estimated using the 'meta' package in R software (V.4.1.3), with double arcsine transformation to convert data, calculating 95% CIs using the Wilson method. We quantified heterogeneity estimates for the pooled estimates of prevalence using the I<sup>2</sup> statistic. Since

considerable heterogeneity was expected (I<sup>2</sup> >50%), we used random effects models in our analyses.

We assessed the possible sources of heterogeneity by performing subgroup and meta-regression analyses. In subgroup analysis, we divided the population into adults, children and mixed groups. Mixed groups were defined as when the studies did not distinguish between adults or children and only reported the overall prevalence of atypical pathogenic infections. We also calculated the prevalence of atypical pathogens in patients with severe pneumonia by different continents. To investigate the prevalence of atypical pathogens for different categories of severe pneumonia, we performed the following analysis: since the classification of severe pneumonia was not

reported in most paediatric studies, for *Chlamydia* and *Mycoplasma*, we conducted a subgroup analysis of non-paediatric studies by pneumonia category. We divided the sample into adults and children in one study,<sup>29</sup> as it presents different prevalence in two groups, respectively, and we also divided a study<sup>30</sup> into the severe community-acquired pneumonia (SCAP) group and severe hospital-acquired pneumonia (SHAP) group for the same reason.

In meta-regression, factors included in the univariate and multivariate analyses were the year of publication, sample size (by treating sample size as a continuous variable, and by comparing sample size greater than or equal to 100 with less than 100), mean age, study population (by comparing adults samples with children samples), region of the study (by comparing studies from Asia with those from other continents), pneumonia categories (by comparing SCAP with other types of pneumonia) and diagnostic methods of the pathogens (by comparing the traditional method of culture and PCR with others). To promote model stability, we only included factors that exhibited significant differences ( $p < 0.05$ ) in the univariate analysis into the multivariate meta-regression model. Sensitivity analyses were conducted on *Chlamydia*, *Mycoplasma* and *Legionella* groups, respectively, to test the robustness of our statistical model. Publication bias of the studies was examined using the Egger's test.<sup>31</sup> All statistical analyses were conducted using R software (V.4.1.3). A  $p$  value of  $< 0.05$  was considered statistically significant.


## Patient and public involvement

No patients were involved in setting the research question, in developing plans for design, interpretation, reporting or implementation of the study. No patients were asked to advise on interpretation or reporting of results.

## RESULTS

A total of 6795 articles were identified from the database searches. After removing duplicates and preliminary screening, 376 studies with full text available were assessed. Through strict screening criteria, we finally included 75 studies ( $n = 18\,379$ ) published between 1985 and 2022 in our meta-analysis (figure 1). Among the studies included, 53 studies reported data for adults ( $n = 10\,404$ ),<sup>4 29 30 32–81</sup> 17 studies for children ( $n = 6652$ )<sup>29 35 82–96</sup> and 7 studies for mixed groups ( $n = 1323$ )<sup>97–103</sup> (online supplemental material 2 and table 1). Forty-eight reported data for *Chlamydia* ( $n = 12\,087$ )<sup>4 30 32–34 39–42 44 46 48–50 53 56 58 60–65 67–70 72 74 75 78–82 84–88 90 91 93 97–99 101 102</sup>, 61 for *Mycoplasma* ( $n = 15\,101$ )<sup>4 30 32–34 36 37 39–50 53–58 60–70 72 74 79–91 93–102</sup> and 56 for *Legionella* ( $n = 11\,144$ ).<sup>4 30 32–34 36–50 52 55 56 58–65 67–70 72–81 84 86 87 92 93 97–101 103</sup>

The most frequent reason for excluding literature was the lack of a complete aetiological analysis. It should be noted that there were four studies<sup>29 52 80 98</sup> that considered the prevalence of *Mycoplasma* and *Chlamydia* as a whole, and we could not obtain more detailed information on their respective prevalence rate; we then excluded this



**Figure 1** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

study when calculating the pooled prevalence of either *Chlamydia* or *Mycoplasma*. Moreover, 27 of the 75 studies were from Asia,<sup>29 43 53 54 59 63 64 67 68 70 75–78 81–83 89 92–96 99–102</sup> 28 from Europe,<sup>30 32–34 37–42 44–47 50–52 56 57 60 61 65 66 71 72 74 97 98</sup> 9 from Africa,<sup>35 36 62 73 84–87 91</sup> 4 from South America,<sup>48 55 69 88</sup> 3 from North America,<sup>4 49 79</sup> 2 from Australia<sup>58 103</sup> and 2 studies<sup>80 90</sup> did not present the exact continents.

All of the included studies were assessed for risk of bias. The quality score of each study was presented in online supplemental material 2 and table 1. Of all the 75 included studies, 56 studies were of high quality and 19 studies were of moderate quality. There were no studies with low quality ratings. The quality scores ranged from 5 to 10 (moderate-to-high quality), indicating satisfactory quality in the meta-analysed literature.

The overall prevalence of atypical pathogens including *Chlamydia*, *Mycoplasma* and *Legionella* in patients with severe pneumonia was 8.1% (95% CI 6.3% to 10.1%;  $I^2=95\%$ ), ranging from 0% to 48.1%, of which the prevalence in adults (7.6%; 95% CI 5.8% to 9.6%;  $I^2=91\%$ ) was slightly lower than that in children (7.8%; 95% CI 3.6% to 13.2%;  $I^2=98\%$ ). The mixed group that did not distinguish adults and children presented a prevalence of 12.1%, which contributed a lot to the overall prevalence (figure 2). SCAP has a greater overall prevalence of 8.96% (95% CI 6.85% to 11.29%,  $I^2=94.5\%$ ) than other types of pneumonia (5.57%, 95% CI 2.91% to 8.96%,  $I^2=94.4\%$ ). In different regions, the prevalence in Europe is highest (10.12%, 95% CI 7.79% to 12.69%,  $I^2=83.4\%$ ), followed by Asia (9.23%, 95% CI 6.00% to 13.04%,  $I^2=96.0\%$ ) and other continents (4.08%, 95% CI 2.11% to 6.59%,  $I^2=90.9\%$ ).

### Chlamydia

In the meta-analysis of the prevalence for each pathogen, the pooled prevalence of *Chlamydia* in patients with severe pneumonia was 1.8% (95% CI 1.0% to 2.9%;  $I^2=91\%$ ), ranging from 0% to 23.1% and the prevalence in children (1.1%; 95% CI 0.06% to 3.0%;  $I^2=92\%$ ) was slightly lower than that in adults (1.8%; 95% CI 0.1% to 2.8%;  $I^2=85\%$ ) (figure 3). Geographically, patients with severe pneumonia had the highest prevalence of *Chlamydia* in Asia at 4.0% (95% CI 1.6% to 7.1%;  $I^2=91\%$ ), followed by Europe at 1.3% (95% CI 0.6% to 2.1%;  $I^2=56\%$ ) and other continents at 0.7% (95% CI 0% to 1.9%;  $I^2=85\%$ ) (online supplemental figure S1). As many studies focused on children did not identify the pneumonia categories, we performed a subgroup analysis of all adults' studies and we found only one *Chlamydia* infection in patients with pneumonia categories other than SCAP.

After we excluded two large studies<sup>82 101</sup> based on sensitivity analysis, the pooled prevalence rate dropped slightly to 1.44% (95% CI 0.77% to 2.26%), but it displayed high heterogeneity ( $I^2=86.4\%$ ). In the meta-regression analysis, the region (Asia or others) of the study that exhibited the highest statistical difference in the univariate analysis ( $p=0.05$ ) accounted for 42.2% of the sources of overall heterogeneity (table 1). The univariate regression

also shows that the prevalence in SCAP is higher than in other pneumonia categories, which also takes 13.14% of the heterogeneity. The diagnostic method of pathogens (PCR vs others) also contributes to the heterogeneity with statistical significance ( $p=0.004$ ). And sample size (continuous), pneumonia categories and diagnostic methods remained statistically significant in the multivariate analysis, indicating that these factors account for a great part of the heterogeneity ( $R^2=41.5\%$ ). The Egger's test indicated that there was no significant publication bias for analysis evaluating the prevalence of *Chlamydia* ( $p=0.052$ ).


### Mycoplasma

The pooled estimated prevalence of *Mycoplasma* in patients with severe pneumonia was 2.8% (95% CI 1.7% to 4.3%;  $I^2=95\%$ ), ranging from 0% to 32.7% and it was more common in children (4.8%; 95% CI 1.3% to 10.1%;  $I^2=98\%$ ) than in adults (1.9%; 95% CI 1.2% to 2.8%;  $I^2=77\%$ ) (figure 4). In terms of regional distribution, the prevalence of *Mycoplasma* in patients with severe pneumonia was highest in Asia (6.1%; 95% CI 3.0% to 10.1%;  $I^2=96\%$ ), followed by Europe (2.1%; 95% CI 1.1% to 3.3%;  $I^2=70\%$ ) and other continents (0.8%; 95% CI 0.1% to 1.7%;  $I^2=75\%$ ) (online supplemental figure S2). In the subgroup analysis of adults, we found that SCAP (2.0%; 95% CI 1.2% to 3.0%;  $I^2=79\%$ ) was more common than hospital-acquired pneumonia (HAP) (1.1%, 95% CI 0.03% to 2.3%,  $I^2=21\%$ ).


Based on the results of the sensitivity analysis, we excluded four studies in children,<sup>82 86 94 95</sup> three of which had the highest prevalence and one with the lowest prevalence; after the exclusion, the prevalence of *Mycoplasma* in patients with severe pneumonia was slightly reduced to 2.24% (95% CI 1.50% to 3.08%), with a heterogeneity of  $I^2=84.4\%$  (95% CI 80.5% to 87.5%). In the univariate meta-regression analysis, the prevalence of *Mycoplasma* was lower in studies with higher mean age ( $p=0.01$ ), accounting for 26.9% of overall heterogeneity; and the diagnostic methods (PCR vs other) also show statistical significance. Region of the studies was also a possible source of heterogeneity accounting for 39.6%, but with weak statistical significance ( $p=0.06$ ) (table 1). As other factors had no obvious relationships with heterogeneity, we did not perform further multivariate meta-regression analysis. The Egger's test did not show evidence of publication bias for analysis evaluating the prevalence of *Mycoplasma* ( $p=0.87$ ).

### Legionella


The prevalence rate of *Legionella* in severe pneumonia was 4.0% (95% CI 2.8% to 5.3%;  $I^2=90\%$ ), ranging from 0% to 30% and adults (4.2%; 95% CI 2.9% to 5.6%;  $I^2=87\%$ ) had a higher prevalence than children (1.4%, 95% CI 0% to 6.4%;  $I^2=94\%$ ) (figure 5). Compared with other regions, Europe (6.3%; 95% CI 3.9% to 9.2%;  $I^2=89\%$ ) had the highest prevalence of *Legionella* in patients with severe pneumonia, followed by Asia (3.6%; 95% CI 2.0% to 5.7%;  $I^2=84\%$ )




**Figure 2** The pooled estimated prevalence of atypical pathogens in patients with severe pneumonia. Displayed values are mean and 95% CIs.



**Figure 3** The estimated prevalence of *Chlamydia* in patients with severe pneumonia. Displayed values are mean and 95% CIs.



**Figure 4** The estimated prevalence of *Mycoplasma* in patients with severe pneumonia. Displayed values are mean and 95% CIs.



**Figure 5** The estimated prevalence of *Legionella* in patients with severe pneumonia. Displayed values are mean and 95% CIs.

and other continents (1.5%; 95% CI 0% to 3.1%;  $I^2=82\%$ ) (online supplemental figure S3). Analysis of 46 adults studies showed that the overall *Legionella* prevalence in adults was 4.2% (95% CI 2.91% to 5.58%;  $I^2=87\%$ ). And detailed pneumonia categories analysis revealed that in 40 SCAP studies, the prevalence of *Legionella* in patients with SCAP was 4.0% (95% CI 2.73% to 5.41%;  $I^2=85\%$ ), which was slightly lower than the other pneumonia categories (5.28%; 95% CI 0.92% to 12.51%;  $I^2=93\%$ ), but there was no significant statistical difference between the two groups ( $p=0.72$ ) and the small sample size of other pneumonia categories ( $n=6$ ) may attribute to this difference.

After a sensitivity analysis, we excluded a large sample size study in children and three studies with the highest prevalence rates<sup>32 40 92</sup> after which the prevalence of *Legionella* in patients with severe pneumonia slightly fell to 3.49% (95% CI 2.5% to 4.6%), with a slightly lower but still significant heterogeneity ( $I^2=84.2\%$ ; 95% CI 80.1% to 87.5%). The individual variable meta-regression analysis revealed that year of publication ( $p<0.0001$ ), sample size, mean age ( $p=0.004$ ) and the diagnostic methods (PCR vs others) were likely related to heterogeneity, and notably, the diagnostic methods (PCR vs others) accounted for 21.22% of overall differences. It indicates the methods with higher accuracy and new diagnostic method may be the possible reason for the heterogeneity of the prevalence. The prevalence was remarkably higher in older reports and older adults. And after multivariate meta-regression analysis, only mean age was strongly associated with heterogeneity ( $p=0.002$ ). Factors included in our multivariate regression explained 12.86% of the total heterogeneity (table 2). The Egger's test indicated the existence of publication bias in the prevalence of *Legionella* ( $p=0.02$ ).

## DISCUSSION

Our meta-analysis identified 75 studies of 18 379 individuals from 6 continents. The main finding is that the overall prevalence of the atypical pathogen in severe pneumonia is 8.1%, and children present a higher prevalence than

adults. In patients with severe pneumonia, the prevalence of *Legionella* was the highest and *Chlamydia* was the lowest. The trend of the prevalence in adults was similar to the overall trend, while in children, *Mycoplasma* was the most common and *Legionella* was rare. Our study also suggests that in adults, atypical pathogens (including *Chlamydia* and *Mycoplasma*) had a higher prevalence in SCAP than that in other types of pneumonia.

Previous research of the prevalence of atypical pathogens in patients with CAP showed that the prevalence of *Mycoplasma* is highest in both adults and children, and *Legionella* had the lowest prevalence, with a rate of 2.7%.<sup>104</sup> Studies based on outpatients with CAP showed a similar conclusion.<sup>105 106</sup> Nevertheless, our study indicates that *Legionella* is the most common atypical pathogen, with a prevalence of 4.0% in both severe pneumonia and SCAP. This finding leads to the inference that *Legionella* is more likely to cause serious infections compared with the other two pathogens, especially in adults. Furthermore, *L. pneumophila* serotype 1 is previously the most-tested and widely-studied *Legionella* spp that causes human pneumonia, but other species have recently been reported, such as *Legionella bozemanii*<sup>34</sup> and *Legionella longbeachae*,<sup>101 107</sup> which are also responsible for severe infections. For *Mycoplasma* and *Chlamydia*, young people displayed a higher prevalence than elderly individuals did in both CAP and SCAP.<sup>108</sup> In our meta-analysis, the prevalence of *Mycoplasma* and *Chlamydia* in severe pneumonia was 2.8% and 1.8%; these rates are significantly lower than a previous study in which non-severe pneumonia had a prevalence of 10.1% and 3.5%, respectively.<sup>104</sup> Therefore, these two pathogens may cause severe lung conditions in only a small percentage of cases. Moreover, Gacouin *et al*<sup>109</sup> found that severe pneumonia due to *C. psittaci* shared similarities with various aspects of severe legionellosis.

In addition, the distribution of pathogens varied according to the geographical region: in Asia, the prevalence of *Mycoplasma* was the highest in patients with severe pneumonia, followed by *Chlamydia* and *Legionella*; however, in Europe,

**Table 2** Multivariate meta-regression for prevalence of *Chlamydia*, and *Legionella* in patients with severe pneumonia

Covariate	Estimate (%)	Lower 95% CI	Upper 95% CI	P value
<i>Chlamydia</i> (n=49)				
Sample size (continuous)	-0.01	-0.02	0.00	0.01
Region (Asia vs others)	0.75	-6.88	21.85	0.30
Category (others vs CAP)	-8.52	-15.16	-1.87	0.01
Diagnostic method (PCR vs others)	-8.15	-14.18	-2.13	0.008
<i>Legionella</i> (n=57)				
Year of publication	-0.25	-0.60	-0.10	0.16
Sample size (continuous)	0.00	-0.01	0.02	0.85
Sample size ( $\geq 100$ vs $<100$ )	-1.90	-9.50	5.71	0.62
Mean age	-0.45	-0.74	-0.15	0.002
Diagnostic method (PCR vs others)	-7.67	-15.56	0.23	0.06

CAP, community-acquired pneumonia; PCR, polymerase chain reaction.

*Legionella* was the most common pathogen with a high prevalence of 6.3%, while *Chlamydia* was the least prevalent. The different testing frequency of atypical pathogens is one reason for the inconsistent prevalence among regions. Compared with other countries, Europe had the highest frequency of patients that underwent testing for atypical pathogens, whereas Africa and South America had a lower frequency; moreover, patients with severe CAP have a lower testing frequency compared with that of non-severe patients.<sup>110</sup> In our study, we only included studies that reported testing for at least one atypical pathogen; these studies were primarily from Asia and Europe, even though we did not restrict the inclusion criteria regarding regions. As there is likely regional variation in the degree of recognition by clinicians and economic conditions, future studies in low-income countries are necessary.

In meta-regression analysis, we found several possible factors for heterogeneity. For *Chlamydia*, we found that *Chlamydia* infection almost exclusively occurred in SCAP, which is consistent with the conventional cognition that *C. pneumoniae* is one of the pathogens associated with CAP, rather than HAP.<sup>105</sup> Additionally, *C. psittaci*, another species of *Chlamydia*, can cause zoonotic disease, although this condition is often contracted outside the hospital because it necessitates a clear history of contact with birds.<sup>8</sup> A recent study inferred that *C. pneumoniae* and *M. pneumoniae* are not related to nosocomial respiratory tract infections in ICU patients.<sup>111</sup> For *Mycoplasma*, the mean age accounted for a part of the heterogeneity, with lower prevalence in older people. This is consistent with the traditional belief that *M. pneumoniae* is more common in children.<sup>112</sup> Although Legionnaires' disease is rare in children, Greenberg *et al.*<sup>113</sup> suggested heightened vigilance to its non-specific clinical manifestations and high mortality rate (33%), especially when empirical antibiotic treatment is ineffective. *Legionella* was also a common microorganism in severe HAP, and previous studies revealed that both CAP<sup>105 114</sup> and HAP (whether or not mechanical ventilation is required)<sup>115</sup> account for a certain proportion of *Legionella* infections. However, other research<sup>116</sup> showed a lower prevalence rate in HAP, from which our results are different. The higher rate of HAP and other pneumonia types displayed in our results may be related to the small sample size of this group. Another factor may be the aquatic properties of *Legionella* spp.<sup>22</sup> Regional water pollution, including in hospitals, can lead to outbreaks of *Legionella* pneumonia. The significant heterogeneity in these analyses demonstrates the need for aetiology analysis to place special emphasis on a thorough description of pneumonia categories and samples.

Regarding the diagnostic method of pathogens detection, we identified several possible reasons to explain the heterogeneity. After we factored this variable into meta-regression analysis, we found the diagnostic method (PCR vs others) demonstrated statistical significance in the prevalence of *Chlamydia* and *Legionella*. However, many studies used multiple test methods and merged the results to calculate the overall prevalence, so the factor cannot be fully explained. The lack of uniform guidelines for the detection of atypical pathogen infections

also led to statistical differences between studies. Furthermore, the latest detection methods used in the studies, like metagenomic next-generation sequencing and transmission electron microscope screening, only included a small sample size in severe pneumonia, which prevented us from further analysis. Some factors that we did not assess might also be related to heterogeneity, such as the diagnostic criteria of severe pneumonia, the distribution of infection throughout different seasons, or whether antibiotics were used prior to microbial testing. Accordingly, future studies should describe these aspects more specifically.

The outbreak of COVID-19 may influence the prevalence of atypical pathogens in severe pneumonia.<sup>117</sup> However, unlike the natural occurrence of CAP in the population, COVID-19 pneumonia is a manually-managed infectious disease with strict quarantine measures for a long period.<sup>118</sup> Therefore, we did not include the study about the atypical pathogen infections in COVID-19. But in the post-pandemic era, analysis of COVID-19 and its co-infection with atypical pathogens may present different insights.

The primary takeaway from our research is that the atypical pathogen is a common cause of severe pneumonia, and the identification of infections should be integral to the effective empirical treatment of severe cases. The high prevalence of the atypical pathogen implies when traditional antibiotic therapy fails to treat severe pneumonia, atypical pathogens infection should be considered. Or we can use antibiotics covering atypical pathogens once severe pneumonia is diagnosed. The empirical antibiotic coverage for CAP or other pneumonia mainly focuses on using penicillin and cephalosporins. But for patients with severe pneumonia, it is important to cover the atypical pathogen infection by using antibiotics such as quinolones, tetracyclines and sulfonamides.

The results of our systematic review should be explained within limited contexts. First, our results may be influenced by the quality of original studies and their reporting bias, and the exclusion of non-English publications likely contributed to the bias. However, based on the Egger's test, only *Legionella* presented publication bias with statistical significance. To reduce such effects, we strictly stipulated literature-screening criteria and excluded studies for special populations, which likely do not represent the prevalence in the whole population. Second, our analysis did not include infection due to *Coxiella burnetii*, one of the atypical pathogens commonly discussed,<sup>119</sup> because there were few relevant reports at the initial search, and only a small number of cases of *C. burnetii* infection exhibit mild-to-moderate pneumonia while severe pneumonia is infrequent.<sup>120</sup> Third, our analysis found substantial heterogeneity; although several factors were identified, there were still some characteristics that could not be assessed, such as the different diagnostic criteria for severe pneumonia. Although we found the diagnostic method (PCR vs others) contributes a lot to the heterogeneity, the detection of pathogens still varies greatly and is hard to be sorted. Additionally, the articles we included

cover a wide time span, and the definition of severe pneumonia has been gradually improved from scratch over time. As shown in online supplemental material 2 and table 2, many old studies only used ICU admission as the inclusion criteria, which prevented us from the further subgroup analysis. Furthermore, the impact of seasonal epidemics and regional outbreaks and different sensitivities and specificities of various laboratory testing methods may contribute to underdiagnosis.<sup>104</sup> Although PCR can provide rapid results,<sup>14 121</sup> a combination of multiple laboratory methods can be more reliable.<sup>122 123</sup>

## CONCLUSIONS

This meta-analysis summarises the prevalence of atypical pathogens in patients with severe pneumonia. Our work demonstrates that atypical pathogens infections are common in severe pneumonia, and covering atypical pathogens in the empirical antibiotic treatment is necessary. Differences in estimated prevalence may be associated with the pneumonia category, the diagnostic method used for detection, the region of the studies and the sample size. These factors should be considered when performing microbiological screening for patients with severe pneumonia, especially when conventional empirical antibiotic therapy is ineffective. Additional studies with large sample sizes, rigorous designs and better testing methods are needed to provide further guidance regarding antibiotic treatment in severe pneumonia.

**Acknowledgements** We would like to thank Editage (www.editage.cn) for English language editing.

**Contributors** SW, JT and LQ conceived and designed the study. Literature search was performed by JT and LQ. SW and JT performed the data analysis and wrote the article. YT and ZS contributed with high subject knowledge. All the authors gave substantial contributions to the work. Every author revised the work critically for important intellectual content. Every author made a final approval of the version to be published. Every author agreed to be accountable for all aspects of the work. ZS is responsible for the overall content of the research as the guarantor.

**Funding** This work was supported by grant #2020SK53611 from the innovation guidance project of Natural Science Foundation of Hunan province, grant #2021JJ31090 from the project of Natural Science Foundation of Hunan province.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,

and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Sidan Wang <http://orcid.org/0000-0002-6506-9848>

## REFERENCES


- 1 Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients. *BMJ* 2021;375:e065871.
- 2 Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. *Clin Infect Dis* 2017;65:1806–12.
- 3 Arnold FW, Summersgill JT, Ramirez JA. Role of atypical pathogens in the etiology of community-acquired pneumonia. *Semin Respir Crit Care Med* 2016;37:819–28.
- 4 Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med* 2015;373:415–27.
- 5 Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. *N Engl J Med* 2015;372:835–45.
- 6 Balis E, Boufas A, Iliopoulos I, et al. Severe community-acquired pneumonia with acute hypoxemic respiratory failure due to primary infection with Chlamydia pneumoniae in a previously healthy adult. *Clin Infect Dis* 2003;36:e155–7.
- 7 Ramakers BP, Heijne M, Lie N, et al. Zoonotic Chlamydia caviae presenting as community-acquired pneumonia. *N Engl J Med* 2017;377:992–4.
- 8 Cheong HC, Lee CYQ, Cheok YY, et al. Chlamydiaceae: diseases in primary hosts and zoonosis. *Microorganisms* 2019;7:146.
- 9 Alves MS, da Silva Cariolano M, Dos Santos Ferreira HL, et al. High frequency of Chlamydia pneumoniae and risk factors in children with acute respiratory infection. *Braz J Microbiol* 2020;51:629–36.
- 10 Cui J, Yan W, Xie H, et al. A retrospective seroepidemiologic survey of Chlamydia pneumoniae infection in patients in Beijing between 2008 and 2017. *PLoS ONE* 2018;13:e0206995.
- 11 Rybarczyk J, Verstele C, Lernout T, et al. Human psittacosis: a review with emphasis on surveillance in Belgium. *Acta Clin Belg* 2020;75:42–8.
- 12 Polkinghorne A, Weston KM, Branley J. Recent history of psittacosis in Australia: expanding our understanding of the epidemiology of this important globally distributed zoonotic disease. *Intern Med J* 2020;50:246–9.
- 13 Hokynar K, Kurkela S, Nieminen T, et al. Parachlamydia acanthamoebae detected during a pneumonia outbreak in southeastern Finland, in 2017–2018. *Microorganisms* 2019;7:141.
- 14 Spoorenberg SMC, Bos WJW, van Hanne E, et al. Chlamydia psittaci: a relevant cause of community-acquired pneumonia in two Dutch hospitals. *Neth J Med* 2016;74:75–81.
- 15 Asner SA, Jatón K, Kyprianidou S, et al. Chlamydia pneumoniae: possible association with asthma in children. *Clin Infect Dis* 2014;58:1198–9.
- 16 Ashraf GM, Tarasov VV, Makhmutova A, et al. The possibility of an infectious etiology of Alzheimer disease. *Mol Neurobiol* 2019;56:4479–91.
- 17 Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. *JAMA* 2002;288:2724–31.
- 18 Beeton ML, Zhang X-S, Uldum SA, et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. *Euro Surveill* 2020;25.
- 19 Chahin A, Opal SM. Severe pneumonia caused by legionella pneumophila: differential diagnosis and therapeutic considerations. *Infect Dis Clin North Am* 2017;31:111–21.
- 20 Spiegelman J, Pedutem T, Francisco MJ. Legionnaires' disease cases at a large community hospital-common and underdiagnosed. *Int J Environ Res Public Health* 2020;17:332.
- 21 Falcone M, Russo A, Tiseo G, et al. Predictors of intensive care unit admission in patients with Legionella pneumonia: role of the time to appropriate antibiotic therapy. *Infection* 2021;49:321–5.
- 22 Cunha BA, Burillo A, Bouza E. Legionnaires' disease. *Lancet* 2016;387:376–85.
- 23 Centers for Disease Control and Prevention (CDC). Legionellosis ---United States, 2000–2009. *MMWR Morb Mortal Wkly Rep* 2011;60:1083–6.
- 24 Barskey AE, Derado G, Edens C. Rising incidence of Legionnaires' disease and associated epidemiologic patterns, United States, 1992–2018. *Emerg Infect Dis* 2022;28:527–38.


- 25 Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:e1–34.
- 26 Cuello-García CA, Schünemann HJ. Update of the agency for healthcare research and quality guidance on using nonrandomized studies in evidence syntheses. *J Clin Epidemiol* 2022;152:307–8.
- 27 VanderPluym JH, Halker Singh RB, Urtecho M, *et al.* Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. *JAMA* 2021;325:2357–69.
- 28 Hu J, Dong Y, Chen X, *et al.* Prevalence of suicide attempts among Chinese adolescents: a meta-analysis of cross-sectional studies. *Compr Psychiatry* 2015;61:78–89.
- 29 Gong C, Zhang T, Luo M, *et al.* Distribution of the atypical pathogens of community-acquired pneumonia to disease severity. *J Thorac Dis* 2018;10:5991–6001.
- 30 Doğan A, Ersoy Çınar Y, Otlı B, *et al.* Investigation of viral and atypical pathogens in patients with pneumonia who need intensive care unit. *FLORA* 2022;27:28–36.
- 31 Egger M, Davey Smith G, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- 32 Woodhead MA, Macfarlane JT, Rodgers FG, *et al.* Aetiology and outcome of severe community-acquired pneumonia. *J Infect* 1985;10:204–10.
- 33 Sørensen J, Cederholm I, Carlsson C. Pneumonia: a deadly disease despite intensive care treatment. *Scand J Infect Dis* 1986;18:329–35.
- 34 Sørensen J, Forsberg P, Håkanson E, *et al.* A new diagnostic approach to the patient with severe pneumonia. *Scand J Infect Dis* 1989;21:33–41.
- 35 Forgie IM, O'Neill KP, Lloyd-Evans N, *et al.* Etiology of acute lower respiratory tract infections in Gambian children: I. Acute lower respiratory tract infections in infants presenting at the hospital. *Pediatr Infect Dis J* 1991;10:33–41.
- 36 Potgieter PD, Hammond JMJ. Etiology and diagnosis of pneumonia requiring ICU admission. *Chest* 1992;101:199–203.
- 37 Woodhead MA. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. *Respiratory Medicine* 1992;86:7–13.
- 38 Rello J, Quintana E, Ausina V, *et al.* A three-year study of severe community-acquired pneumonia with emphasis on outcome. *Chest* 1993;103:232–5.
- 39 Moine P, Vercken JB, Chevret S, *et al.* Severe community-acquired pneumonia. etiology, epidemiology, and prognosis factors. French study group for community-acquired pneumonia in the intensive care unit. *Chest* 1994;105:1487–95.
- 40 Almirall J, Mesalles E, Klamburg J, *et al.* Prognostic factors of pneumonia requiring admission to the intensive care unit. *Chest* 1995;107:511–6.
- 41 Leroy O, Santré C, Beuscart C, *et al.* A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. *Intensive Care Med* 1995;21:24–31.
- 42 Cosentini R, Blasi F, Raccanelli R, *et al.* Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae. *Respiration* 1996;63:61–5.
- 43 Lee KH, Hui KP, Tan WC, *et al.* Severe community-acquired pneumonia in Singapore. *Singapore Med J* 1996;37:374–7.
- 44 Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. *Thorax* 1997;52:17–21.
- 45 Ruiz M, Ewig S, Marcos MA, *et al.* Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. *Am J Respir Crit Care Med* 1999;160:397–405.
- 46 Ruiz M, Ewig S, Torres A, *et al.* Severe community-acquired pneumonia. risk factors and follow-up epidemiology. *Am J Respir Crit Care Med* 1999;160:923–9.
- 47 Vegelin AL, Bissumbhar P, Joore JC, *et al.* Guidelines for severe community-acquired pneumonia in the Western world. *Neth J Med* 1999;55:110–7.
- 48 Luna CM, Famiglietti A, Absi R, *et al.* Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. *Chest* 2000;118:1344–54.
- 49 Park DR, Sherbin VL, Goodman MS, *et al.* The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. *J Infect Dis* 2001;184:268–77.
- 50 Rello J, Bodi M, Mariscal D, *et al.* Microbiological testing and outcome of patients with severe community-acquired pneumonia. *Chest* 2003;123:174–80.
- 51 Tomic V, Igor D, Franc S, *et al.* Severe community-acquired pneumonia: etiology, empiric antibiotic treatment and outcome. *J Infect Dis Pharmacother* 2003;6:1–13.
- 52 Vallés J, Mesalles E, Mariscal D, *et al.* A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. *Intensive Care Med* 2003;29:1981–8.
- 53 Kawai S, Ochi M, Nakagawa T, *et al.* Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan. *J Infect Chemother* 2004;10:352–8.
- 54 Reechaipichitkul W, Pisprasert V. Severe community-acquired pneumonia (CAP) treated at srinagarind hospital, Khon Kaen, Thailand. *Southeast Asian J Trop Med Public Health* 2004;35:430–3.
- 55 Díaz A, Alvarez M, Callejas C, *et al.* Clinical picture and prognostic factors for severe community-acquired pneumonia in adults admitted to the intensive care unit. *Arch Bronconeumol* 2005;41:20–6.
- 56 Gutiérrez F, Masiá M, Rodríguez JC, *et al.* Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. *Clin Microbiol Infect* 2005;11:788–800.
- 57 Templeton KE, Scheltinga SA, van den Eeden WCJFM, *et al.* Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. *Clin Infect Dis* 2005;41:345–51.
- 58 Wilson PA, Ferguson J. Severe community-acquired pneumonia: an Australian perspective. *Intern Med J* 2005;35:699–705.
- 59 Yang ST, Philip Eng W-YC. Severe community-acquired pneumonia requiring intensive care in Singapore, an Asian perspective. *Chest* 2007;132:558C.
- 60 Strålin K, Olcén P, Törnqvist E, *et al.* Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. *Scand J Infect Dis* 2010;42:426–34.
- 61 Cillóniz C, Ewig S, Polverino E, *et al.* Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax* 2011;66:340–6.
- 62 Hartung TK, Chimbayo D, van Oosterhout JJG, *et al.* Etiology of suspected pneumonia in adults admitted to a high-dependency unit in Blantyre, Malawi. *Am J Trop Med Hyg* 2011;85:105–12.
- 63 Choi S-H, Hong S-B, Ko G-B, *et al.* Viral infection in patients with severe pneumonia requiring intensive care unit admission. *Am J Respir Crit Care Med* 2012;186:325–32.
- 64 Dagaonkar RS, Udhwadia ZF, Sen T, *et al.* Severe community acquired pneumonia in mumbai, india: etiology and predictive value of the modified british thoracic society rule. *Am J Respir Crit Care Med* 2012;18.
- 65 Zobel K, Martus P, Pletz MW, *et al.* Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. *BMC Pulm Med* 2012;12:6.
- 66 Alzubaidy R, Ehrmann S, Lhommet C, *et al.* Severe community acquired pneumonia: implementation of polymerase chain reaction diagnosis in clinical practice. *Intensive Care Med* 2013;39:S312.
- 67 Ishiguro T, Takayanagi N, Yamaguchi S, *et al.* Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. *Intern Med* 2013;52:317–24.
- 68 Lee Y-T, Chen S-C, Chan K-C, *et al.* Impact of infectious etiology on the outcome of Taiwanese patients hospitalized with community acquired pneumonia. *J Infect Dev Ctries* 2013;7:116–24.
- 69 Arancibia F, Cortes CP, Valdés M, *et al.* Importance of legionella pneumophila in the etiology of severe community-acquired pneumonia in santiago, chile. *Chest* 2014;145:290–6.
- 70 Ishida T, Tachibana H, Ito A, *et al.* Clinical characteristics of severe community-acquired pneumonia among younger patients: an analysis of 18 years at a community hospital. *J Infect Chemother* 2014;20:471–6.
- 71 Vallés J, Martín-Loeches I, Torres A, *et al.* Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. *Intensive Care Med* 2014;40:572–81.
- 72 Walden AP, Clarke GM, McKechnie S, *et al.* Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the genosept cohort. *Crit Care* 2014;18:R58.
- 73 Elshamly M, Nour MO, Omar AMM. Clinical presentations and outcome of severe community-acquired pneumonia. *Egypt J Chest Dis Tuberc* 2016;65:831–9.
- 74 Voiriot G, Visseaux B, Cohen J, *et al.* Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. *Crit Care* 2016;20:375.


- 75 Mahendra M, Jayaraj BS, Limaye S, *et al.* Factors influencing severity of community-acquired pneumonia. *Lung India* 2018;35:284–9.
- 76 Qin T, Ren H, Chen D, *et al.* National surveillance of Legionnaires' disease, China, 2014–2016. *Emerg Infect Dis* 2019;25:1218–9.
- 77 Xie Y, Du J, Jin W, *et al.* Next generation sequencing for diagnosis of severe pneumonia: China, 2010–2018. *J Infect* 2019;78:158–69.
- 78 Wu X, Li Y, Zhang M, *et al.* Etiology of severe community-acquired pneumonia in adults based on metagenomic next-generation sequencing: a prospective multicenter study. *Infect Dis Ther* 2020;9:1003–15.
- 79 de Mangou A, Combe A, Coolen-Allou N, *et al.* Severe community-acquired pneumonia in reunion Island: epidemiological, clinical, and microbiological characteristics, 2016–2018. *PLoS ONE* 2022;17:e0267184.
- 80 Guillot P, Delamaire F, Painvin B, *et al.* Safety of early discontinuation of an empiric combination antibiotic regimen in severe community-acquired pneumonia: the STOP study. *Ann Intensive Care* 2022;12.
- 81 Qu J, Zhang J, Chen Y, *et al.* Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China. *Emerg Microbes Infect* 2022;11:556–66.
- 82 Samransamruajkit R, Jitchaiwat S, Wachirapaes W, *et al.* Prevalence of Mycoplasma and Chlamydia pneumonia in severe community-acquired pneumonia among hospitalized children in Thailand. *Jpn J Infect Dis* 2008;61:36–9.
- 83 Zhang Q, Guo Z, Bai Z, *et al.* A 4 year prospective study to determine risk factors for severe community acquired pneumonia in children in Southern China. *Pediatr Pulmonol* 2013;48:390–7.
- 84 Howie SRC, Morris GAJ, Tokarz R, *et al.* Etiology of severe childhood pneumonia in the Gambia, West Africa, determined by conventional and molecular microbiological analyses of lung and pleural aspirate samples. *Clin Infect Dis* 2014;59:682–5.
- 85 Jroundi I, Mahraoui C, Benmessaoud R, *et al.* The epidemiology and aetiology of infections in children admitted with clinical severe pneumonia to a university hospital in rabat, Morocco. *J Trop Pediatr* 2014;60:270–8.
- 86 Breiman RF, Cosmas L, Njenga M, *et al.* Severe acute respiratory infection in children in a densely populated urban slum in Kenya, 2007–2011. *BMC Infect Dis* 2015;15:95.
- 87 Salih KMA, El-Samani E-F, Bilal JA, *et al.* Clinical and laboratory potential predictors of blood culture positivity in under five children with clinically severe pneumonia-Khartoum -sudan. *J Clin Diagn Res* 2015;9:SC04–7.
- 88 Jonnalagadda S, Rodríguez O, Estrella B, *et al.* Etiology of severe pneumonia in Ecuadorian children. *PLoS ONE* 2017;12:e0171687.
- 89 Koh JWJC, Wong JJ-M, Sultana R, *et al.* Risk factors for mortality in children with pneumonia admitted to the pediatric intensive care unit. *Pediatr Pulmonol* 2017;52:1076–84.
- 90 Thea DM, Seidenberg P, Park DE, *et al.* Limited utility of polymerase chain reaction in induced sputum specimens for determining the causes of childhood pneumonia in resource-poor settings: findings from the pneumonia etiology research for child health (PERCH) study. *Clin Infect Dis* 2017;64:S289–300.
- 91 El-Nawawy A, Ramadan M-F, Antonios M-M, *et al.* Bacteriologic profile and susceptibility pattern of mechanically ventilated paediatric patients with pneumonia. *J Glob Antimicrob Resist* 2019;18:88–94.
- 92 Mojtahedi S-Y, Rahbarimanesh A, Noorbakhsh S, *et al.* Urinary antigens and PCR can both be used to detect *Legionella pneumophila* in children's hospital-acquired pneumonia. *Eur J Transl Myol* 2019;29:8120.
- 93 Krittigamas P, Ruengorn C. Differentiating viral and bacterial pneumonia by clinical manifestations among children in Chiang Mai, Thailand. *J Med Assoc Thai* 2020;103:1345–53.
- 94 Su DQ, Huang HL, Zhuo ZQ. Pathogen distribution and bacterial resistance in children with severe pneumonia: a single-center retrospective study. *Medicine (Baltimore)* 2021;100:e27128.
- 95 Zhou Y, Shan Y, Cui Y, *et al.* Characteristics and outcome of severe *Mycoplasma pneumoniae* pneumonia admitted to PICU in Shanghai: a retrospective cohort study. *Crit Care Explor* 2021;3:e0366.
- 96 Tran Quang K, Tran Do H, Pham Hung V, *et al.* Study on the co-infection of children with severe community-acquired pneumonia. *Pediatr Int* 2022;64:e14853.
- 97 Pachon J, Prados MD, Capote F, *et al.* Severe community-acquired pneumonia. etiology, prognosis, and treatment. *Am Rev Respir Dis* 1990;142:369–73.
- 98 Torres A, Serra-Batllés J, Ferrer A, *et al.* Severe community-acquired pneumonia. epidemiology and prognostic factors. *Am Rev Respir Dis* 1991;144:312–8.
- 99 Dahmash NS, Chowdhury MN. Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study. *Thorax* 1994;49:71–6.
- 100 Tan YK, Khoo KL, Chin SP, *et al.* Aetiology and outcome of severe community-acquired pneumonia in Singapore. *Eur Respir J* 1998;12:113–5.
- 101 Phares CR, Wangroongsarb P, Chandra S, *et al.* Epidemiology of severe pneumonia caused by *Legionella longbeachae*, *Mycoplasma pneumoniae*, and *Chlamydia pneumoniae*: 1-year, population-based surveillance for severe pneumonia in Thailand. *Clin Infect Dis* 2007;45:e147–55.
- 102 Li Y, Jiang J, Deng P. Application of transmission electron microscopy in the etiology diagnosis of severe pneumonia via BALF: a retrospective study. *Respirology* 2018;23:68.
- 103 Kübler A, Maguire F, Sidebotham D. Venovenous extracorporeal membrane oxygenation for treating very severe pneumonia in Aotearoa New Zealand: a 16-year experience. *N Z Med J* 2021;134:56–66.
- 104 Marchello C, Dale AP, Thai TN, *et al.* Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. *Ann Fam Med* 2016;14:552–66.
- 105 Capelastegui A, España PP, Bilbao A, *et al.* Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. *BMC Infect Dis* 2012;12:134.
- 106 Chen J, Li X, Wang W, *et al.* The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort. *Infect Drug Resist* 2019;12:2335–41.
- 107 Graham FF, White PS, Harte DJG, *et al.* Changing epidemiological trends of legionellosis in New Zealand, 1979–2009. *Epidemiol Infect* 2012;140:1481–96.
- 108 Dumke R, Schnee C, Pletz MW, *et al.* Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011–2012. *Emerg Infect Dis* 2015;21:426–34.
- 109 Gacouin A, Revest M, Letheulle J, *et al.* Distinctive features between community-acquired pneumonia (CAP) due to *Chlamydia pneumoniae* and CAP due to *Legionella pneumophila* admitted to the intensive care unit (ICU). *Eur J Clin Microbiol Infect Dis* 2012;31:2713–8.
- 110 Gramegna A, Sotgiu G, Di Pasquale M, *et al.* Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. *BMC Infect Dis* 2018;18:677.
- 111 Hagel S, Schmitt S, Kesselmeier M, *et al.* M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections. *Infection* 2019;47:471–4.
- 112 Meyer Sauter PM, Berger C. Proadrenomedullin in Mycoplasma pneumoniae community-acquired pneumonia in children. *Clin Infect Dis* 2021;73:e1769–71.
- 113 Greenberg D, Chiou CC, Famigilletti R, *et al.* Problem pathogens: paediatric legionellosis -- implications for improved diagnosis. *Lancet Infect Dis* 2006;6:529–35.
- 114 Cillóniz C, Torres A, Niederman M, *et al.* Community-acquired pneumonia related to intracellular pathogens. *Intensive Care Med* 2016;42:1374–86.
- 115 Esperatti M, Ferrer M, Theessen A, *et al.* Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. *Am J Respir Crit Care Med* 2010;182:1533–9.
- 116 Dagan A, Epstein D, Mahagneh A, *et al.* Community-acquired versus nosocomial Legionella pneumonia: factors associated with legionella-related mortality. *Eur J Clin Microbiol Infect Dis* 2021;40:1419–26.
- 117 Perico L, Benigni A, Casiraghi F, *et al.* Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. *Nat Rev Nephrol* 2021;17:46–64.
- 118 Surkova E, Nikolayevskiy V, Drobniowski F. False-positive COVID-19 results: hidden problems and costs. *Lancet Respir Med* 2020;8:1167–8.
- 119 Lim WS, Baudouin SV, George RC, *et al.* BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009;64 Suppl 3:iii1–55.
- 120 Marrie TJ. Coxiella burnetii pneumonia. *Eur Respir J* 2003;21:713–9.
- 121 Wagner K, Springer B, Imkamp F, *et al.* Detection of respiratory bacterial pathogens causing atypical pneumonia by multiplex lightmix® RT-PCR. *Int J Med Microbiol* 2018;308:317–23.
- 122 Pierre DM, Baron J, Yu VL, *et al.* Diagnostic testing for Legionnaires' disease. *Ann Clin Microbiol Antimicrob* 2017;16:59.

123 Chaudhry R, Valavane A, Sreenath K, *et al.* Detection of *Mycoplasma pneumoniae* and *Legionella pneumophila* in patients

having community-acquired pneumonia: a multicentric study from new Delhi, India. *Am J Trop Med Hyg* 2017;97:1710–6.







## Supplementary Material 1. Literature Search Strategies

### PubMed:

#1 (severe pneumonia [MeSH Terms]) OR (severe pneumon\*[Title/Abstract]) OR (severe community acquired pneumon\*[Title/Abstract])

#2 atypical pathogens OR atypical pneumonia OR mycoplasm\* OR Pneumonia, Mycoplasma OR legionell\* OR legionnaire\* OR Legionellosis OR Legionnaires' disease OR chlamydi\* OR chlamydia pneumonia OR chlamydia pneumoniae OR chlamydial pneumonia

#1 AND #2

### Embase:

#1 'severe pneumonia'/exp OR 'severe pneumon\*':ab,ti OR 'severe community acquired pneumon\*':ab,ti

#2 'atypical pathogen\*' OR 'atypical pneumonia\*' OR 'mycoplasm\*' OR 'pneumonia, mycoplasma' OR 'legionell\*' OR 'legionnaire\*' OR 'chlamydi\*' OR 'chlamydia pneumonia' OR 'chlamydia pneumoniae' OR 'chlamydial pneumonia'

#1 AND #2

### Web of Science:

#1 TI=(severe pneumon\*) OR AB=(severe pneumon\*) OR TI=(severe community acquired pneumon\*) OR AB=(severe community acquired pneumon\*)

#2 TS=(atypical pathogen\* OR atypical pneumon\* OR mycoplasm\* OR Pneumonia, Mycoplasma OR legionell\* OR Legionellosis OR Legionnaires' disease OR chlamydi\* OR chlamydia pneumonia OR chlamydia pneumoniae OR chlamydial pneumonia)

#1 AND #2

### The Cochrane Library:

#1 (severe pneumonia): ti,ab,kw OR (severe community acquired pneumonia):ti,ab,kw

#2 (atypical pathogen\* OR atypical pneumonia OR mycoplasm\* OR Pneumonia, Mycoplasma OR legionell\* OR legionnaire\* OR chlamydi\* OR chlamydia pneumonia OR chlamydia pneumoniae OR chlamydial pneumonia)

#1 AND #2

**Abbreviation:** MeSH, medical Subject Headings in MEDLINE.

## Supplementary Material 2

**Supplementary Table 1: Characteristics of Studies of the Prevalence of Chlamydia, Mycoplasma, and Legionella in Patients with Severe Pneumonia.**

Study	Region	Age group	Pneumonia category	Pathogen	Total/Case	Study period	Diagnostic method	Diagnostic criteria	Quality Score*
<b>Adults=53</b>									
Woodhead et al,1985	United Kingdom#	>14y	CAP*	MP, LP, CP	50/16	1972-1981	Serology	Admitted to ICU	8
Sörensen et al,1986	Sweden	>14y	CAP*	MP, LP, C.psittaci	30/6	1981-1982	Serology, Culture	Admitted to ICU	7
Sörensen et al,1989	Sweden	>14y	CAP	MP, LP, LB, C.psittaci	36/4	1984-1987	Serology, Culture	Admitted to ICU	9
Potgieter et al,1992	South Africa	>14y	CAP, HAP, AP, ICP	MP, LP	178/6	1987.01-1989.12	Serology, Culture	Admitted to ICU	9
Woodhead et al,1992	United Kingdom#	>15y	CAP*	MP, LP	60/11	1987.01-1987.12	Serology, Culture	Admitted to ICU	10
Rello et al, 1993	Spain	>23y	CAP	LP	35/8	1988.01-1990.12	Serology, UA	Admitted to ICU	8
Moine et al,1994	France#	≥15y	CAP*	MP, LP, C.psittaci	132/6	1987.06-1989.12	Serology, Culture	Admitted to ICU	10
Almirall et al,1995	Spain	Adults	CAP, HAP	MP, LP, C.psittaci	127/28	1986,03-1989,02	Serology, Culture	Admitted to ICU	9
Leroy et al, 1995	France	>17y	CAP*	CP, MP, LP	299/7	1987.01-1991.12	Serology, Culture	Admitted to ICU	7
Cosentini et al, 1996	Italy	>23y	CAP	MP, CP, LP	61/9	1992.07-1993.06	Culture, indirect immunofluorescent	ATS1993	8
Lee et al, 1996	Singapore	>19y	CAP	MP, LP	59/3	1991.06-1993.02	Serology, Culture	Admitted to ICU	9
Hirani et al, 1997	UK	>15y	CAP*	MP, CP, LP	57/12	1984.01-1993.12	Serology, ELISA	IDSA/ATS	7
Ruiz et al-1, 1999	Spain	Adults	CAP	MP, LP	64/0	1996.10-1997.12	Serology, Culture	BTS1987	9
Ruiz et al-2, 1999	Spain	Adults	CAP*	MP, LP, CP, C.psittaci	89/11	1996.10-1998.09	Serology, Culture, UA	ATS1993	8
Vegelin et al, 1999	Netherlands	>19y	CAP*	MP, LP	62/3	1992-1996	Culture	IDSA/ATS	6

Luna et al, 2000	Argentina	>17y	CAP	MP, CP, LP	39/7	1997.10-1998.09	UA, IFA	IDSA/ATS	8
Park et al, 2001	USA	Adults	CAP	MP, CP, LP	72/11	1994.06-1996.05	Serology, Culture	ATS1993	8
Rello et al, 2003	Spain#	Adults	CAP	MP, CP, LP	210/26	1993.01-2000.01	Serology, Culture, UA	ATS2001	8
Tomic et al, 2003	Slovenia	>20y	CAP	Atypical bacteria	55/4	1998.01-1998.12	Serology, UA	ATS2001	9
Vallés et al, 2003	Germany#	Adults	HAP	LP	96/18	1993.01-2000.01	Serology, bronchoalveolar lavage, UA	APACHE	8
Kawai et al, 2004	Japan	≥15y	CAP	MP, CP	60/1	1998.01-2000.12	Serology	JRS2000	9
Reechaipichitkul et al, 2004	Thailand	≥15y	CAP	MP	105/1	1999.01-2001.12	Serology	ATS2001	8
Diaz et al, 2005	Chile	> 15y	CAP*	MP, LP	113/3	1999-2001	Serology, Culture, UA	Admitted to ICU	8
Gutierrez et al, 2005	Spain	>15y	CAP	MP, CP, LP	123/14	1999.10-2001.10	CF test, UA	PSI: IV or V	10
Templeton et al, 2005	Netherlands#	≥18y	CAP	MP	28/0	2000.9.1-2002.9.30	Serology, Culture, RT-PCR	PSI: IV or V	9
Wilson et al, 2005	Australia	≥18y	CAP	MP, LP, CP	44/3	2001.1-2003.7	Culture, UA, PCR	PSI	7
Yang et al, 2007	Singapore	Adults	CAP*	LP	103/2	over a 2-year period	/	Admitted to ICU	7
Stralin et al, 2010	Sweden	>18y	CAP	MP, CP, LP	80/5	1999.11-2002.04	Culture, UA, PCR	PSI, CRB-65: 2-4	8
Cillóniz et al, 2011	Spain	Adults	CAP*	MP, LP, CP	301/22	1996.11-2008.07	Serology, Culture, UA	PSI: V	10
Hartung et al, 2011	Malawi	> 18y	CAP	MP, LP, CP, C.pittaci	51/0	2006.02-2006.09	PCR, Culture	Admitted to ICU	10
Choi et al, 2012	Korea	≥18y	CAP, HCAP	MP, LP, CP	198/5	2010-2011	Culture, UA, PCR	IDSA/ATS2007	9
Dagaonkar et al, 2012	India	Adults	CAP*	MP, LP, CP	19/2	over 18 months	/	mBTS	7
Zobel et al, 2012	Germany#	>18y	CAP*	MP, CP, LP	105/21	2001.01-2006.12	Culture, UA, PCR	CRB, CRB-65	9

Alzubaidy et al, 2013	France	Adults	CAP	MP	69/7	/	PCR	Admitted to ICU	6
Ishiguro et al, 2013	Japan	Adults	CAP	MP, LP, CP, C.psittaci	133/33	2002.01-2011.11	Serology, UA	IDSA/ATS2 007	7
Lee et al, 2013	Taiwan, China	≥15y	CAP	MP, CP, LP	88/15	2007.01-2008.12	Serology, UA	PSI>90	9
Arancibia et al, 2014	Chile#	> 18y	CAP*	MP, LP, CP	104/19	2005.01-2006.06	Culture, UA, Serology	ATS2001	8
Ishida et al, 2014	Japan	> 15y	CAP	MP, LP, CP, C.psittaci	461/52	1994.07-2012.07	Culture, Serology, UA	IDSA/ATS2 007	10
Valles et al, 2014	Spain	> 18y	CAP, HCAP, ICP	MP, LP, CP	726/43	2011.04-2012.12	Culture, UA, Serology	Admitted to ICU	7
Walden et al, 2014	European #	>18y	CAP	MP, CP, LP	1135/85	2005.09-2009.10	Serology, Culture, UA	IDSA/ATS	9
Jain et al, 2015	USA#	≥18y	CAP	MP, CP, LP	784/16	2010.01-2012.06	PCR, UA	PSI: IV or V	10
Elshamly et al, 2016	Egypt	Adults	CAP	LP	54/1	2015.8-2016.3	Culture, UA	IDSA/ATS2 007	7
Voiriot et al, 2016	France	Adults	CAP	MP, CP, LP	174/14	2011.10-2015.6	mPCR	PSI/SAPS	7
Gong et al, 2018	China#	≥18y	CAP	MP, CP	797/7	since 2014	RT-PCR	CTS2013	9
Mahendra et al, 2018	India	Adults	CAP	LP, CP	42/0	2015.03-2015.07	Culture, Serology, UA	CURB-65 > 2	9
Qin et al, 2019	China#	Adults	CAP	LP	286/11	2014-2016	UA, Culture	CSRD2016	9
Xie et al, 2019	China	18-85y	NR*	LP	178/4	2010.01-2018.06	Culture, NGS	IDSA/ATS	9
Wu et al, 2020	China#	≥18y	CAP*	LP, CP	329/45	2018.06-2020.2	mNGS	IDSA/ATS	8
De Mangou et al, 2022	USA	>18y	CAP	MP, CP, LP	572/9	2016.01-2018.12	UA, PCR	ATS2019	8
Dogan et al, 2022	Turkey	≥18y	CAP	MP, CP, LP	63/4	2016.11-2017.10	PCR	IDSA/ATS2 009	8
Dogan et al, 2022	Turkey	≥18y	HAP	MP, CP, LP	137/4	2016.11-2017.10	PCR	IDSA/ATS2 009	8
Guillot et al, 2022	/	> 18y	CAP	MP, CP, LP	856/26	over 6 years	UA	Admitted to ICU	5

Qu et al, 2022	China#	>18y	CAP*	MP, CP, LP	275/62	2018.06-2019.12	Culture, UA, mNGS	Admitted to ICU	8
<b>Children=17</b>									
Forgie et al,1991	Gambia	1-9y	ALRI	MP, CP	74/12	1987.06-1988.05	Serology, Culture	WHO1988	7
Samransamruajkit et al,2008	Thailand	1m-15y	CAP	MP, CP	52/25	2005-2006	Serology	WHO1991	8
Zhang et al, 2013	China	1m-5y	CAP	MP	707/78	2007.01-2010.12	Serology, Culture, ELISA	WHO2005	8
Howie et al,2014	Gambia	2-59m	NR	MP, LP, CP	55/0	2007-2009	Culture, PCR	WHO	8
Jroundi et al,2014	Morocco	2-59m	NR	MP, CP	684/10	2010.11-2011.02	Culture, PCR	WHO2005	8
Breiman et al,2015	Kenya	< 5y	SARI	MP, LP, CP	815/0	2007.03-2011.02	Culture, PCR	WHO2008	10
Salih et al,2015	Sudan	< 5y	NR	MP, LP, CP	189/6	2011.01-2012.06	Culture	WHO2005	8
Jonnalagadda et al,2017	Ecuador	2-59m	NR	MP, CP	406/3	2008.02-2010.04	PCR	WHO	9
Koh et al,2017	Singapore	1m-18y	CAP, HAP	MP	237/10	2010-2014	Culture, Serology, PCR	WHO2014	9
Thea et al, 2017	Southeast Asia, South Africa#	1m-59m	CAP	MP, CP	1166/38	2011.08-2014.01	mPCR	WHO, Radiography	8
Gong et al, 2018	China#	<18y	CAP	MP, CP	274/19	since 2014	RT-PCR	CTS2013	9
El-Nawawy et al, 2019	Egypt	1m-12y	CAP*	MP, CP	43/8	2015.05-2018.03	IgA, ELISA	admitted to PICU, mechanical ventilation	9
Mojtahedi et al, 2019	Iran#	<18y	HAP	LP	96/19	2013-2014	PCR	Admitted to ICU	8
Krittigamas et al, 2020	Thailand	1m-18y	CAP	MP, CP, LP	208/1	2017.10-2020.04	RT-PCR	WHO2014	9
Su et al, 2021	China	<14y	CAP	MP	734/142	2016.01-2019.12	Culture, PCR	WHO	7
Zhou et al, 2021	China	1m-18y	CAP	MP	817/203	2017.01-2019.12	Serology, PCR	Admitted to ICU	9
Tran et al, 2022	Vietnam	2m-15y	CAP	MP	95/8	2020.03-2020.08	RT-PCR	WHO/BTS2013	8

Mix=7									
Pachon et al,1990	Spain	Mix	CAP*	MP, LP, C.psittaci	67/7	1985-1987	Serology, Culture	Admitted to ICU	8
Torres et al,1991	Spain	Mix	CAP*	MP, LP, C.psittaci	92/19	1984.01-1987.12	Serology, Culture	Admitted to ICU	7
Dahmash et al,1994	Saudi Arabia	> 12y	CAP, HAP	MP, LP, CP	113/5	1991.09-1992.12	Serology, Culture	Admitted to ICU	10
Tan et al,1998	Singapore	>12y	CAP*	MP, LP	57/6	1989.01-1993.05	Serology, Culture	Admitted to ICU	8
Phares et al, 2007	Thailand#	Mix	CAP	MP, CP, LP, LL	755/130	2003.09-2004.08	Serology, UA, PCR	Admitted to ICU	7
Li et al, 2018	China	Mix	NR	MP, CP	106/26	/	TEM	Admitted to ICU	5
Kübler et al, 2021	New Zealand	Mix	NR	LP	133/8	2004.01-2020.08	Culture	VV-ECMO	7
<p>HCAP=healthcare-associated pneumonia; ICP=Immunocompromised patient; AP=aspiration pneumonia; ICP=Immunocompromised pneumonia; ALRI=acute lower respiratory tract infections; SARI=severe acute respiratory infection; MP=Mycoplasma pneumoniae; LP=Legionella pneumophila; LB=Legionella Bozemanii; LL=Legionella longbeachae; C.psittaci=Chlamydia psittaci; CP=Chlamydia pneumoniae; IDSA=Infectious Diseases Society of America; ATS=American Thoracic Society; APACHE =Acute Physiology and Chronic Health Evaluation; mBTS=modified British Thoracic Society rule; JRS=Janpan Respiratory Society; CSRD=Chines e Society of Respiratory Diseases; SAPS=Simplified Acute Physiologic Score; WHO=the World Health Organization; UA=urine antigen testing; PCR=polymerase chain reaction; NGS=next generation sequencing; NR=not reported</p> <p>* Study excludes immunocompromised patients</p> <p># multicenter study</p>									

**\*The citations of Diagnostic Criteria have been provided in Supplementary Table 2.**

**\* Quality assessment score: Low quality = 0–3; Moderate quality = 4–7; High quality = 8–11.**

**AHRQ Assessment Criteria: (Yes=1, No=2, Unclear=3; Answering “Yes” gets 1 score, otherwise get 0 score.)**

Q1. Define the source of information (survey, record review)

Q2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications

Q3. Indicate time period used for identifying patients

Q4. Indicate whether or not subjects were consecutive if not population-based

Q5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants

Q6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)

Q7. Explain any patient exclusions from analysis

Q8. Describe how confounding was assessed and/or controlled

Q9. If applicable, explain how missing data were handled in the analysis

Q10. Summarize patient response rates and completeness of data collection

Q11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained

**Supplementary Table 2. Details on the severity diagnosis of pneumonia**

<b>Diagnostic Criteria of Severe Pneumonia</b>	<b>Number of Studies</b>
<b>Admitted to ICU</b>	<b>26</b>
<b>IDSA/ATS criteria</b>	<b>19</b>
ATS1993	3
ATS2001	4
ATS2007	4
IDSA/ATS2009	2
IDSA/ATS2019	1
<b>WHO criteria</b>	<b>13</b>
WHO1988	1
WHO1991	1
WHO2005	3
WHO2008	1
WHO2013	1
WHO2014	2
<b>BTS criteria (BTS1987; modified BTS)</b>	<b>2</b>
<b>PSI score</b>	<b>8</b>
<b>CRB/CURB-65</b>	<b>3</b>
<b>APACHE</b>	<b>1</b>
<b>Others: CSRD2016, CTS2013 and JRS2000</b>	<b>3</b>
<b>Total</b>	<b>75</b>